Multiplex Biomarker Imaging Market size was estimated at USD 561.2 Mn in 2021, growing at a CAGR of 12.1% during the forecast period 2022-2028. Increase in the adoption of the multiplex biomarker in immunology and oncology research, growing R&D investments by pharmaceutical and biotechnology companies, increase in demand for personalized medicine, and innovation of newer technologies in biomarker imaging are anticipated to fuel the multiplex biomarker imaging market size over the forecast period. Moreover, increase in preference for companion diagnostics and advantages of multiplex biomarker imaging over conventional methods are anticipated to boost the multiplex biomarker imaging market report over the forecast years. However, the high cost of the instruments, ethical issues of biomarker imaging techniques, and stringent regulatory policies are anticipated to impede the growth of market. Multiplex biomarker imaging is a technique carried to characterize and analyze the disease present in the body. Biomarkers are used in clinical studies to determine the diseases progress. Multiplex biomarkers have a major role in the medical industry and these are used in alone or combination to determine the characteristics and evaluate as an indicator of biological process. Multiplex biomarkers also help in the study of biological system by providing analysis to check the expression of various biomarkers. In August 2017, Quanterix launched high-sensitivity instrument Quanterix SR-Plex and assays for multiplex biomarker detection.